Clinical Trial Update: Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on SHR-1020 plus albumin-bound paclitaxel for second-line pancreatic cancer treatment reported efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• SHR-1020

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: UNKNOWN